文献速递胸部肿瘤

血浆与肿瘤标本中综合癌症基因组谱检测的一致性

Concordance between Comprehensive Cancer Genome Profiling in Plasma and Tumor Specimens.
PubMed 文献 · J Thorac Oncol · 2017-07-24

本研究在82例非鳞状非小细胞肺癌患者中,系统比较了覆盖39个基因的大规模平行测序液体活检(NEOliquid)与认证中心病理实验室常规组织检测的一致性。结果显示两者一致性为98%,NEOliquid灵敏度高于70%,特异性为100%。不一致病例包括血浆循环肿瘤DNA不足以及血浆中检出已知驱动突变而常规组织分析未检测的情况。

要点

  • 在82例匹配血/组织样本中,NEOliquid与组织常规检测的一致性为98%。
  • NEOliquid灵敏度高于70%,特异性为100%。
  • 不一致原因包括循环肿瘤DNA不足及组织常规未检测的驱动突变。

核心结论

  • NEOliquid可准确可靠地检测癌症患者血浆中临床相关驱动基因改变。

研究设计与样本

  • 研究纳入82例非鳞状非小细胞肺癌患者,匹配血/组织样本,比较覆盖39个基因的大规模平行测序液体活检(NEOliquid)与认证中心病理实验室常规诊断检测。

主要发现

  • 在82例匹配血/组织样本中,NEOliquid与组织常规检测的一致性为98%。
  • NEOliquid灵敏度高于70%,特异性为100%。
  • 不一致病例包括血浆循环肿瘤DNA不足以及血浆中检出已知驱动突变(如IDH1 R132H、KIF5B-RET或MET外显子14)而常规组织分析未检测的情况。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Detection of somatic genomic alterations in the plasma of patients with cancer ("liquid biopsy") are increasingly being used in the clinic. However, the concordance of alterations identified in liquid biopsies with those detected in cancer specimens is not routinely being determined. METHODS: We sought to systematically compare alterations found by a massively parallel sequencing liquid biopsy assay covering 39 genes (NEOliquid [NEO New Oncology GmbH, Köln, Germany]) with those identified through routine diagnostic testing in a certified central pathology laboratory in a cohort of patients with nonsquamous NSCLC. NEOliquid is based on enrichment of the genomic territory of interest by hybrid capture and is thus capable of detecting point mutations, small insertions and deletions, copy number alterations, and gene rearrangements/fusions in a single assay. RESULTS: In a cohort of 82 patients with matched blood/tissue samples, the concordance between NEOliquid and tissue-based routine testing was 98%, the sensitivity of NEOliquid was higher than 70%, and the specificity was 100%. Discordant cases included those with insufficient amounts of circulaating tumor DNA in plasma and cases in which known driver mutations (e.g., isocitrate dehydrogenase (NADP(+)), 1 systolic gene [IDH1] R132H, kinesin family member 5B gene [KIF5b-ret proto-oncogene [RET], or MNNG HOS Transforming gene [MET] exon 14) were found in the plasma but were not interrogated by routine tissue analyses. CONCLUSIONS: In summary, NEOliquid offers accurate and reliable detection of clinically relevant driver alterations in plasma of patients with cancer.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Müller JN, Falk M, Talwar J, et al. Concordance between Comprehensive Cancer Genome Profiling in Plasma and Tumor Specimens. J Thorac Oncol. 2017. PMID: 28751246. doi:10.1016/j.jtho.2017.07.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。